|
| |
Transave Inc.Transave is a biotechnology company focused on the site specific treatment of lung disease. The company’s goal is to achieve the leadership role in the treatment of lung diseases via the use of its proprietary Sustained release Lipid Inhalation Targeting (SLIT™) technology. The Company’s low risk business model is focused predominantly on developing inhaleable sustained release formulations of already approved drugs, for both its own commercialization and for partners.
Transave’s SLIT™ technology offers four unique advantages in the treatment of lung disease over other existing inhalation therapies:
1. the ability to attain a prolonged therapeutic effect of a drug in the lung by sustained release via inhalation therapy; 2. the ability to target and enhance the uptake of the drug into the diseased cells; 3. the reduction of side effects associated with systemic delivery; and 4. the potential to reduce drug resistance through a sustained therapeutic dose. The end result is a less frequently administered drug with an enhanced therapeutic index. Transave's SLIT™ technology is amenable to delivery of both low and high molecular weight compounds (e.g., peptides, proteins and genes). It can be used to improve current injectable or inhalation products (e.g., traditional already approved pharmaceuticals) as well as to develop new improved lung disease products (e.g., proteins and genes).
| Contact Details: |
| 11 Deer Park DriveSuite 117 |
| Monmouth Jct. |
| New Jersey |
| 08852 |
| United States of America |
| Tel: | 732-438-9434 |
| Fax: | 732-438-9435 |
| Email: | agorman@transaveinc.us |
| WWW: | www.transaveinc.com/
|
|
Loading...
|
Press Releases on Transave Inc.:
|
 |
| Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections |
19th October, 2009 |
Transave, Inc. |
MONMOUTH JUNCTION, N.J., Oct. 19 /PRNewswire/ -- Transave Inc., today reported additional positive clinical trial results on its lead investigational drug, ARIKACE(TM) (liposomal amikacin for
|
| Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM) |
25th June, 2009 |
Transave, Inc. |
Company Also Receives Patent Covering ARIKACE for Once-Daily Treatment of Pseudomonas Lung Infections
MONMOUTH JUNCTION, N.J., June 25 /PRNewswire/ -- Cystic Fibrosis Foundation Therapeutics Inc.,
|
| Transave Completes Enrollment in Arikace(TM) Phase II Bronchiectasis Study |
21st April, 2009 |
Transave, Inc. |
Presently No Approved Treatments
MONMOUTH JUNCTION, N.J., April 21 /PRNewswire/ -- Transave, Inc., today reported completion of patient enrollment in a Phase II study evaluating the safety and
|
| Transave, Inc. Secures $12.5 Million in New Financing |
2nd October, 2008 |
Transave, Inc. |
STRENGTH OF PHASE II DATA FOR LEAD DRUG CANDIDATE ARIKACE(TM) DRIVES CONTINUED CLINICAL EXPANSION
MONMOUTH JUNCTION, N.J., Oct. 2 /PRNewswire/ -- Transave, Inc., a biopharmaceutical company focused
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 322 times since April 2007, the link to the organisation's website has been followed 68 times Recent Search Terms used to find this page: transave inc | . Search for more companies in Monmouth Jct. Search for more companies in New Jersey This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Transave Inc. |
